Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

Rhea-AI Summary

Vericel (NASDAQ:VCEL), a leading provider of advanced therapies for sports medicine and severe burn care, has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025, at 10:30 a.m. ET (7:30 a.m. PT).

Interested parties can access a webcast of the presentation through the Investor Relations section of Vericel's website at http://investors.vcel.com.

News Market Reaction

+2.50%

1 alert

+2.50% News Effect

On the day this news was published, VCEL gained 2.50%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 43^rd Annual J.P. Morgan Healthcare Conference at 10:30 a.m. ET (7:30 a.m. PT) on Wednesday, January 15, 2025.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2025 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

FAQ

When is Vericel (VCEL) presenting at the J.P. Morgan Healthcare Conference 2025?

Vericel (VCEL) is scheduled to present at the J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 10:30 a.m. ET (7:30 a.m. PT).

How can investors watch Vericel's (VCEL) J.P. Morgan Healthcare Conference presentation?

Investors can watch Vericel's presentation via webcast through the Investor Relations section of the company's website at http://investors.vcel.com.

What markets does Vericel (VCEL) operate in?

Vericel (VCEL) operates in the advanced therapies market, specifically focusing on sports medicine and severe burn care markets.

Which annual healthcare conference is Vericel (VCEL) participating in for 2025?

Vericel is participating in the 43rd Annual J.P. Morgan Healthcare Conference in 2025.